Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin

Journal of Thrombosis and Haemostasis : JTH
H C WhinnaF C Church

Abstract

Factor (F)Xa has 11 gamma-carboxylated glutamic acid (Gla) residues that are involved in calcium-dependent membrane binding. The serpin antithrombin (AT) is an important physiological regulator of FXa activity in an inhibition reaction that is enhanced by heparin. Recently, Rezaie showed that calcium further enhanced the heparin-catalyzed AT inhibition of FXa by promoting 'ternary complex' formation, and these results showed a role for the gamma-carboxyl-glutamate (Gla)-domain of FXa. In this study, we used recombinant FXa mutants to assess the role of individual Gla residues in augmenting or antagonizing the AT-heparin inhibition reaction in the presence of calcium. In the absence of heparin, AT inhibition of plasma and the recombinant FXas were essentially equivalent. Similar to plasma-derived FXa, calcium increased about 3-fold the inhibition rate of wild-type recombinant FXa by AT-heparin over that in the presence of EDTA. Interestingly, three different effects were found with the recombinant FXa Gla-mutants for AT-heparin inhibition: (i) Gla-->Asp 14 and 29 were enhanced without calcium; (ii) Gla-->Asp 16 and 26 were not enhanced by calcium; and (iii) Gla-->Asp 19 was essentially the same as wild-type recombinant FXa. Thes...Continue Reading

References

Sep 1, 1986·The Biochemical Journal·V EllisV V Kakkar
Jan 1, 1986·The Biochemical Journal·V EllisV V Kakkar
Oct 10, 1995·Proceedings of the National Academy of Sciences of the United States of America·H BrandstetterW Bode
Apr 15, 1997·Annals of Internal Medicine·D P Thomas, H R Roberts
Aug 1, 1997·Protein Expression and Purification·A E RudolphJ P Miletich
Sep 4, 1997·The New England Journal of Medicine·J I Weitz
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·K KamataS H Kim
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·A C PikeE Persson
Nov 27, 1999·The Journal of Biological Chemistry·S J Bauman, F C Church
May 12, 2000·Hematology/oncology Clinics of North America·T Whiteman, H I Hassouna
May 23, 2000·Lancet·B Dahlbäck
Jun 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·H MizunoT Morita
Jan 31, 2002·Annual Review of Medicine·Agnes Y Y Lee, Jack Hirsh
Apr 20, 2002·Blood·Jack Hirsh, Agnes Y Y Lee
Sep 17, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Dougald M MonroeHarold R Roberts
Jan 14, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Kenneth G MannKathleen Brummel
Feb 26, 2003·The New England Journal of Medicine·Paul M RidkerUNKNOWN PREVENT Investigators
Jul 2, 2003·Biochemistry·Stephanie X WangRobert J Fletterick

❮ Previous
Next ❯

Citations

Aug 12, 2009·BMC Infectious Diseases·Saira SarfrazAnwar A Siddiqui
Aug 17, 2011·Thrombosis Research·Ivan StevicAnthony K C Chan
Mar 21, 2017·Journal of Pharmacological Sciences·Kaname SekiTakaaki Senbonmatsu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.